Cat. No.: HY-16445B

CNDAC hydrochloride

Customer Review

Based on 1 Customer Validation

CNDAC hydrochloride is a metabolite of the orally active agent Sapacitabine (HY-16445), and a nucleoside analog. CNDAC hydrochloride induces DNA damage and apoptosis.

For research use only. We do not sell to patients.

Purity: 98.01%
CAS No.: 134665-72-8
Formula: C₁₀H₁₃ClN₄O₄
Molecular Weight:288.69

Storage:

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

CNDAC hydrochloride Chemical Structure

CAS No.: 134665-72-8

Size

Price

Stock

Quantity

Amount: USD 0.00

* Please select Quantity before adding items.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biological Activity
- Description
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Solvent & Solubility
- In Vitro
Purity & Documentation
References
Help & FAQs
Classifications
Bioz

Biological Activity

Description

CNDAC hydrochloride is a metabolite of the orally active agent Sapacitabine (HY-16445), and a nucleoside analog. CNDAC hydrochloride induces DNA damage and apoptosis^[1]^[2].

All DNA/RNA Synthesis Isoforms :

Cellular Effect

Cell Line	Type	Value	Description	References
A-375	IC₅₀	1.4 μM Compound: 1i	Tested in vitro against A-375 cell line human melanoma Tested in vitro against A-375 cell line human melanoma	[PMID: 8277499]
COLO 320	IC₅₀	1.4 μM Compound: 1i	Tested in vitro against colo-320 human colon adenocarcinoma Tested in vitro against colo-320 human colon adenocarcinoma	[PMID: 8277499]
HOS-TE85	IC₅₀	23.6 μM Compound: 1i	Tested in vitro against MNNG/HOS cell line human osteosarcoma Tested in vitro against MNNG/HOS cell line human osteosarcoma	[PMID: 8277499]
HT-1080	IC₅₀	0.53 μM Compound: 1i	Tested in vitro against HT1080 cell line human fibrosarcoma Tested in vitro against HT1080 cell line human fibrosarcoma	[PMID: 8277499]
KATO III stomach cancer cell line	IC₅₀	55.6 μM Compound: 1i	Tested in vitro against KATO-III human stomach adenocarcinoma Tested in vitro against KATO-III human stomach adenocarcinoma	[PMID: 8277499]
KB	IC₅₀	5.2 μM Compound: 1i	Tested in vitro inhibitory activity against human oral epidermoid carcinoma KB cells Tested in vitro inhibitory activity against human oral epidermoid carcinoma KB cells	[PMID: 8277499]
KKLS	IC₅₀	350 μM Compound: 1i	Tested in vitro against KKLS human stomach adenocarcinoma Tested in vitro against KKLS human stomach adenocarcinoma	[PMID: 8277499]
L1210	IC₅₀	0.53 μM Compound: 1i	Tested in vitro inhibitory activity against murine leukemia L1210 Tested in vitro inhibitory activity against murine leukemia L1210	[PMID: 8277499]
MCF7	IC₅₀	1.75 μM Compound: 1i	Tested in vitro against MCF-7 human breast adenocarcinoma Tested in vitro against MCF-7 human breast adenocarcinoma	[PMID: 8277499]
MKN-45	IC₅₀	15.9 μM Compound: 1i	Tested in vitro against MKN-45 human stomach adenocarcinoma Tested in vitro against MKN-45 human stomach adenocarcinoma	[PMID: 8277499]
OST	IC₅₀	22.2 μM Compound: 1i	Tested in vitro against OST human osteosarcoma Tested in vitro against OST human osteosarcoma	[PMID: 8277499]
PC-13	IC₅₀	86.8 μM Compound: 1i	Tested in vitro against PC-13 human lung large cell carcinoma Tested in vitro against PC-13 human lung large cell carcinoma	[PMID: 8277499]
PC-8	IC₅₀	15.9 μM Compound: 1i	Tested in vitro against PC-8 human lung adenocarcinoma Tested in vitro against PC-8 human lung adenocarcinoma	[PMID: 8277499]
PC-9	IC₅₀	15.3 μM Compound: 1i	Tested in vitro against PC-9 human lung adenocarcinoma Tested in vitro against PC-9 human lung adenocarcinoma	[PMID: 8277499]
QG-95	IC₅₀	138 μM Compound: 1i	Tested in vitro against QG-95 human squamous cell carcinoma Tested in vitro against QG-95 human squamous cell carcinoma	[PMID: 8277499]
ST-KM-1	IC₅₀	9.71 μM Compound: 1i	Tested in vitro against ST-KM human stomach adenocarcinoma Tested in vitro against ST-KM human stomach adenocarcinoma	[PMID: 8277499]
SW48	IC₅₀	>350 μM Compound: 1i	Tested in vitro against SW-48 human colon adenocarcinoma Tested in vitro against SW-48 human colon adenocarcinoma	[PMID: 8277499]

In Vitro

CNDAC has a unique mechanism of action: after incorporation into DNA, it induces single-strand breaks (SSBs) that are converted into double-strand breaks (DSBs) when cells go through a second S phase^[1].
Lack of Rad51D and XRCC3 sensitizes cells to CNDAC (0-1 μM; 24 h)^[1].
CNDAC (0-100 μM; 3 days) inhibits proliferation of HL-60 and THP-1 cells^[2].
CNDAC (0-10 μM; 3-6 days) induces apoptosis in HL-60 and THP-1 cells^[2].
CNDAC (6 μM; 48 h) induces cell cycle arrest in the G2 phase following a delayed S phase in HCT116 cells^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Viability Assay^[1]

Cell Line:

Rad51D-deficient 51D1, Rad51D-complemented 51D1.3, wild-type AA8 and XRCC3-deficient irs1SF CHO cells
Concentration:

0-1 μM
Incubation Time:

24 h
Result:

Inhibited cell survival with IC₅₀s of 0.006, 0.32, 0.48 and 0.0053 μM against Rad51D-deficient 51D1, Rad51D-complemented 51D1.3, wild-type AA8 and XRCC3-deficient irs1SF cell lines, respectively.

Cell Proliferation Assay^[2]

Cell Line:

HL-60 and THP-1 cells
Concentration:

0-100 μM
Incubation Time:

3 days
Result:

Inhibited proliferation with IC₅₀s of 1.5832 μM and 0.84 μM against HL-60 and THP-1 cells, respectively.

Apoptosis Analysis^[2]

Cell Line:

HL-60 and THP-1 cells
Concentration:

0, 0.5, 1, 2, 3, 4, 5 and 10 μM
Incubation Time:

3, 4, 5, and 6 days
Result:

Induced apoptosis in both cells.

Cell Cycle Analysis^[3]

Cell Line:

HCT116
Concentration:

6 μM
Incubation Time:

48 h
Result:

36 and 36% of cells were arrested in late-S and G2/M phases, respectively.

In Vivo

CNDAC (20mg/kg; i.p.; daily for 10 days) shows antitumor activity in mice^[4].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

CDF1 mice, P388 tumor model^[4]
Dosage:

20 mg/kg
Administration:

Intraperitoneal injection, daily for 10 days
Result:

Greatly increased the survival time and survival rate.

Chemical Information

CAS No. 134665-72-8
Appearance Solid
Molecular Weight 288.69
Formula C₁₀H₁₃ClN₄O₄
Color White to off-white
SMILES

O=C(N=C(N)C=C1)N1[C@H]2[C@@H](C#N)[C@H](O)[C@@H](CO)O2.Cl
Shipping

Room temperature in continental US; may vary elsewhere.
Storage

4°C, sealed storage, away from moisture

* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

Solvent & Solubility

In Vitro:

DMSO : 125 mg/mL (432.99 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

View the Complete Stock Solution Preparation Table

Preparing Stock Solutions

View the Complete Stock Solution Preparation Table

Concentration Solvent Mass

1 mg

5 mg

10 mg

Concentration

Solvent

Mass

1 mM

3.4639 mL

17.3196 mL

34.6392 mL

5 mM

0.6928 mL

3.4639 mL

6.9278 mL

10 mM

0.3464 mL

1.7320 mL

3.4639 mL

Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.

Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

Molarity Calculator

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Concentration Concentration

Volume Volume

Molecular Weight Molecular Weight

Dilution Calculator

Concentration _(start) × Volume _(start) = Concentration _(final) × Volume _(final)

Concentration _(start) Concentration _(start)

Volume _(start) Volume _(start)

Concentration _(final) Concentration _(final)

Volume _(final) Volume _(final)

Purity & Documentation

Select Batch:

Purity: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (279 KB)
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

References

[1]. Liu XJ, et al. Sapacitabine, the prodrug of CNDAC, is a nucleoside analog with a unique action mechanism of inducing DNA strand breaks. Chin J Cancer. 2012 Aug;31(8):373-80. [Content Brief]

[2]. Jagan S, et al. Bone Marrow and Peripheral Blood AML Cells Are Highly Sensitive to CNDAC, the Active Form of Sapacitabine. Adv Hematol. 2012;2012:727683. [Content Brief]

[3]. Serova M, et al. Antiproliferative effects of sapacitabine (CYC682), a novel 2'-deoxycytidine-derivative, in human cancer cells. Br J Cancer. 2007 Sep 3;97(5):628-36. [Content Brief]

[4]. Azuma A, et al. Nucleosides and nucleotides. 122. 2'-C-cyano-2'-deoxy-1-beta-D-arabinofuranosylcytosine and its derivatives. A new class of nucleoside with a broad antitumor spectrum. J Med Chem. 1993 Dec 24;36(26):4183-9. [Content Brief]

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Complete Stock Solution Preparation Table

Optional Solvent	Concentration Solvent Mass	1 mg	5 mg	10 mg	25 mg
DMSO	1 mM	3.4639 mL	17.3196 mL	34.6392 mL	86.5981 mL
	5 mM	0.6928 mL	3.4639 mL	6.9278 mL	17.3196 mL
	10 mM	0.3464 mL	1.7320 mL	3.4639 mL	8.6598 mL
	15 mM	0.2309 mL	1.1546 mL	2.3093 mL	5.7732 mL
	20 mM	0.1732 mL	0.8660 mL	1.7320 mL	4.3299 mL
	25 mM	0.1386 mL	0.6928 mL	1.3856 mL	3.4639 mL
	30 mM	0.1155 mL	0.5773 mL	1.1546 mL	2.8866 mL
	40 mM	0.0866 mL	0.4330 mL	0.8660 mL	2.1650 mL
	50 mM	0.0693 mL	0.3464 mL	0.6928 mL	1.7320 mL
	60 mM	0.0577 mL	0.2887 mL	0.5773 mL	1.4433 mL
	80 mM	0.0433 mL	0.2165 mL	0.4330 mL	1.0825 mL
	100 mM	0.0346 mL	0.1732 mL	0.3464 mL	0.8660 mL

Keywords

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent:

Product Name:
CAS No.:
Species:
Purity:
Quantity:

CNDAC hydrochloride

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Drug Metabolite Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

All DNA/RNA Synthesis Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

CNDAC hydrochloride

Apoptosis Compound Library

Cell Cycle/DNA Damage Compound Library

Metabolism/Protease Compound Library

Anti-Cancer Compound Library

Anti-Aging Compound Library

Reprogramming Compound Library

Anti-Lung Cancer Compound Library

Anti-Blood Cancer Compound Library

Anti-Cancer Metabolism Compound Library

Drug Metabolite Library

Cell Death Library

Anti-Hematopathy Compound Library

Bioactive Compound Library Max

MCE Bioactive Compound Library

Bioactive Compound Library

Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library

High-Throughput Bioactive Compound Library

All DNA/RNA Synthesis Isoforms

Biological Activity

Chemical Information

Solvent & Solubility

Purity & Documentation

References

Help & FAQs

Complete Stock Solution Preparation Table

CNDAC hydrochloride Related Classifications

HY-16445B Related Classifications